AltaRex expands its platform
AltaRex is to apply its antigen-targeted antibody approach to the treatment of chronic hepatitis B. The company is to conduct proof-of-concept experiments in its laboratories in collaboration with Dr Lorne Tyrell of the University of Alberta. AltaRex specialises in the development and commercialisation of antigen-targeted monoclonal antibodies, notably for treating cancer.